Ferring Pharmaceuticals has agreed to acquire Gameto, a cell-engineering company focused on fertility treatments, in a deal valued at up to $1.38 billion. The transaction centers on Gameto’s platform to enable more precise, scalable cell-based approaches for reproductive medicine, with Ferring positioning the acquisition as a way to accelerate its next wave of fertility assets. The deal underscores how large biopharma players are moving beyond single assets toward enabling technologies—particularly in areas where manufacturing complexity and patient heterogeneity have historically slowed pipeline translation. For Gameto, the combination offers a route to expand development resources and potentially broaden clinical programs. Key commercial and clinical details such as the specific lead programs and the timeline for post-merger development were not provided in the snippet, but the headline valuation signals a meaningful strategic priority for Ferring in fertility innovation. —